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Abstract. Recurrence is a major problem following the treatment of aggressive central
giant cell granuloma (CGCG). The aim of this study was to compare the frequency
of recurrence between patients who received calcitonin nasal spray after curettage
of CGCGs and those who did not. A double-blind clinical trial was designed.
Patients were allocated to one of two groups: those in the calcitonin group
underwent curettage and received calcitonin salmon nasal spray 200 IU/day once a
day for 3 months after surgery; those in the control group underwent curettage of
CGCGs and received a placebo once a day for 3 months after surgery. All patients
were followed for 5 years after surgery. Twenty-four patients were treated in the two
groups. There was no difference in age, sex, tumour size, or tumour location
between the two groups (P > 0.05). Eight of the 24 patients (33.3%) had
recurrences during the follow-up period: one in the calcitonin group (9.1%) and
seven in the control group (53.8%). Analysis of the data demonstrated a significant
difference between the two study groups (P = 0.033). It appears that calcitonin nasal
spray may reduce the frequency of recurrence in aggressive CGCGs in the mandible
and maxilla.0901-5027/060756 + 04 # 2016 International Association of Oral and Maxillofacial SurgeR. Tabrizi1, S. Fardisi2, B. Zamiri1,
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Available online 15 March 2016Central giant cell granuloma (CGCG) is a
benign lesion of the jawbones. The inci-
dence of CGCG is about 0.00011% of the
general population.1 CGCGs have vari-
able behaviours and clinical presentations,ranging from large lesions with aggressive
behaviour to small isolated lesions.2
The clinical signs and symptoms and
the radiographic and histological features
are the main factors differentiatingnon-aggressive (indolent) from more ag-
gressive lesions.3 Lesions larger than 5 cm
and/or recurrent lesions are considered
aggressive lesions based on clinical char-
acteristics. The non-aggressive lesionsons. Published by Elsevier Ltd. All rights reserved.
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Table 1. Comparison of variables between the two groups.
Variables
Group 1
Calcitonin group
Group 2
Control group P-value
Tumour location 0.47a
Mandible 4 6
Maxilla 7 7
Sex 0.64a
Male 5 6
Female 6 7
Tumour size, mean  SD (cm) 6.40  0.88 6.26  0.97 0.71b
Age, mean  SD (years) 24.36  4.29 24.61  4.64 0.83b
SD, standard deviation.
a Fisher’s exact test.
b Independent t-test.are asymptomatic with no radiographical-
ly visible cortical perforation or root
resorption.4
Local curettage is the conventional
treatment for CGCGs. En bloc resection
has been suggested for aggressive
CGCGs. The recurrence rate following
local curettage in aggressive CGCGs is
between 16% and 48%.5 En bloc resection
is associated with the lowest recurrence
rate.6 However, en bloc resection results in
various degrees of deformity and requires
complex reconstruction procedures.3
In the past two decades, various phar-
macological therapies for CGCGs have
been described.7 Pharmacological agents
prevent or at least minimize the extensive
and mutilating surgical procedures char-
acterized by detrimental functional out-
comes and preserve vital structures and
facial contours.7 Pharmacological agents
that have been used successfully include
intra-lesional corticosteroid injections and
systemic treatment with calcitonin or in-
terferon alpha-2a (IFN-a2a).7,8 Harris in-
troduced calcitonin therapy for CGCGs.9
The mode of action of calcitonin in the
treatment of CGCGs is antagonistic oste-
oclastic bone resorption, or direct action
on other cell types within the lesion.10
Calcitonin has been considered a viable
option for the treatment of CGCGs. It is
suggested for multiple lesions, recurrent
lesions, and aggressive lesions.10
In studies reported in the literature,
calcitonin has been applied for the treat-
ment of CGCGs either alone or as an
adjunct agent.11 However, it has not been
used to prevent recurrence in the manage-
ment of CGCGs. Thus, this study was
performed to assess the use of calcitonin
after curettage of aggressive CGCGs to
determine whether it reduces the frequen-
cy of recurrence or not. It was hypothe-
sized that calcitonin would decrease
recurrence after conventional curettage
of CGCGs of the jaws.
Materials and methods
A double-blind randomized clinical trial
was designed. The sample was derived
from the population of patients referred
to the oral and maxillofacial surgery de-
partment of a medical university in Shiraz,
Iran, between 1 September 2006 and 31
October 2010. The study was approved by
the necessary medical ethics committee
and has been registered at ClinicalTrials.-
gov (registration ID NCT02358304).
Subjects eligible for inclusion had a
clinically aggressive CGCG and under-
went curettage. All subjects had computed
tomography (CT) scans taken beforesurgery. Participants with a systemic dis-
ease affecting bone healing, a brown tu-
mour proven by laboratory test
(parathyroid hormone, calcium phospha-
tase), pregnancy, recent corticosteroid
therapy, and those who refused enrolment
or could not continue for private or social
reasons, were excluded from the study.
The diagnosis of CGCG was made ini-
tially by histopathological examination.
Aggressive CGCGs were defined as
lesions with a diameter >5 cm on CT scan
views, with perforation of the buccal and
lingual plates or root resorption.
Thirty patients were allocated randomly
to two groups. Patients in the calcitonin
group (n = 15) underwent curettage of
CGCGs and received calcitonin salmon
nasal spray 200 IU/day once a day for 3
months after the surgery. Patients in the
control group (n = 15) underwent curet-
tage of CGCGs and received a placebo
once a day for 3 months after surgery.
Patients were followed by a maxillofacial
surgeon who did not participate in the
surgeries and was blinded to the group
allocation of subjects. Furthermore, none
of these surgeons was aware of the re-
search. Patients were blinded to the type of
drugs they had received after surgery.
All patients were followed up for 5
years after the operations. Cases of recur-
rence were documented by clinical and
radiographic examinations and confirmed
by histopathological analysis.
Age, sex, location (maxilla or mandi-
ble), and tumour size were considered as
variables. Calcitonin was the predictive
factor of the study. Recurrence of the
CGCGs determined the outcome of
the study.
Statistical analysis
Statistical analyses were performed using
IBM SPSS Statistics for Windows, version
19.0 (IBM Corp., Armonk, NY, USA). A
pre-protocol analysis was conducted. TheShapiro–Wilk test was used to document
normally distributed age of the samples.
The independent t-test was applied to
compare age and tumour size between
the groups (treatment group with calcito-
nin and control group). Fisher’s exact test
was applied to assess the frequency of
recurrence and variables (tumour location
and sex) between the two groups.
Results
A final total of 24 patients were studied in
the two groups: 11 in the calcitonin group
and 13 in the control group. Six of the
initial 30 patients dropped out at random;
these patients did not follow the study
protocol, or failed to complete the fol-
low-up. The calcitonin group (treatment
group) comprised five males and six
females and the control group comprised
six males and seven females. There was
no difference between the two groups in
sex distribution (P = 0.64). The mean pa-
tient age was 24.36  4.29 years in the
calcitonin group and 24.61  4.64 years
in the control group. Comparison of the
mean age between the groups did not
show a statistically significant difference
(P = 0.83) (Table 1).
The mean tumour size was
6.40  0.88 cm in the calcitonin group
and 6.26  0.97 cm in the control group.
Evaluation of tumour size did not demon-
strate a significant difference between the
groups (P = 0.71). In the calcitonin group,
seven patients had CGCGs in the maxilla
and four had CGCGs in the mandible. In
the control group, seven patients had
CGCGs in the maxilla and six had CGCGs
in the mandible. There was no statistically
significant difference in tumour location
(maxilla or mandible) between the groups
(P = 0.47) (Table 1).
The mean time to recurrence was
23.5  8.75 months (Table 2). Eight of
24 patients (33.3%) had a recurrence.
One patient (9.1%) in the calcitonin group
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Table 2. Description of the patients with recurrence.
Recurrence
case Group Sex
Age
(years) Site
Time of recurrence
(months)
Tumour
size (cm)
1 1 Female 24 Maxilla 33 8
2 2 Female 29 Maxilla 27 7
3 2 Male 19 Maxilla 18 8
4 2 Male 28 Maxilla 26 7
5 2 Female 18 Maxilla 10 7
6 2 Male 26 Maxilla 22 6
7 2 Male 25 Maxilla 36 6
8 2 Female 22 Maxilla 16 7
Table 3. Evaluation of the recurrence rate (study outcome) between the two groups.
Outcome
Group 1
Calcitonin group
Group 2
Control group Fisher’s exact test
Recurrent lesion 1 7 P = 0.033
No recurrence 10 6and seven patients (53.8%) in the control
group had a recurrence during the 5-year
follow-up. Analysis of the data demon-
strated a significant difference between the
two groups in this regard (P = 0.033) (Ta-
ble 3). All patients with recurrence under-
went en bloc resection. None of the
patients with a resected lesion had a sec-
ondary recurrence.
The variables age, sex, tumour location,
and tumour size were compared between
patients with and without recurrence irre-
spective of calcitonin use. Eight of 14
patients (57.1%) with CGCGs in the max-
illa had a recurrence. None of the patients
with mandibular lesions had a recurrence.
There was a significant difference in re-
currence between the mandible and max-
illa (P = 0.006). Results did not reveal a
significant difference for age or sex be-
tween patients with and without recur-
rence (P > 0.05). There was a
significant difference in tumour size be-
tween the recurrence group and the group
without recurrence (P = 0.003) (Table 4).
Discussion
In cases of aggressive CGCG, extensive
surgical procedures resulting in functionalTable 4. Effect of variables on the frequency of r
Variables With recur
Tumour location 
Mandible 0 
Maxilla 8 
Sex 
Male 4 
Female 4 
Tumour size, mean  SD (cm) 5.97  0
Age, mean  SD (years) 23.87  3
a Fisher’s exact test.
b Independent t-test.and aesthetic deformities and the high
recurrence rate following conventional
curettage have prompted surgeons to seek
an effective therapeutic strategy. Giant
cells may arise from peripheral blood
mononuclear cells that are recruited by
the spindle-shaped stromal cells.2 These
spindle-shaped cells are osteoblast-like
cells that express alkaline phosphatase
and are capable of osteoid formation. They
are also able to support osteoclast forma-
tion and cause tumour-like lesions.2
The treatment of CGCGs includes con-
servative surgical procedures and pharma-
cological agents such as local
corticosteroids, IFN-a, and calcitonin
injections. Lesions are considered aggres-
sive CGCG if they are larger than 5 cm in
diameter, show rapid growth, cause tooth
displacement, root resorption, cortical
bone thinning, or perforation, and have
a high recurrence rate (20–70%). En bloc
resection has been recommended for such
cases.12 At present, there are other (non)
surgical options that should be considered
as the first-line treatment for an aggressive
CGCG.
Histological, biochemical, molecular,
or genetic markers should not be consid-
ered as predictive factors for the biologicalecurrence, irrespective of the use of calcitonin.
rence Without recurrence P-value
0.006a
10
6
0.55a
7
9
.76 7.06  0.78 0.003b
.97 24.81  4.67 0.51bbehaviour of CGCG lesions. Pharmaco-
logical agents have usually been used to
prevent or minimize extensive surgical
procedures.12 Calcitonin is a polypeptide
hormone made up of 32 amino acids, and
is secreted by the parafollicular thyroid
C-cells. It decreases circulating levels of
calcium via the inhibition of the activity of
osteoclasts; this, in turn, destroys mineral-
ized bones. In jaw lesions, calcitonin inhi-
bits their growth via the effects mediated
by the calcitonin receptor (CTR).11 Giant
cells have been shown to express osteo-
clastic markers, such as tartrate-resistant
acid phosphatase (TRAP), vitronectin, and
CTR, and can resorb lacunar bone in
vitro.13 Aggressive CGCGs have higher
CTR expression. Also, Nogueira et al.
reported no significant difference in
CTR expression in the different clinical
forms of CGCGs.14
Calcitonin is used as an adjunct for the
treatment of CGCGs. Calcitonin has been
shown to reduce the size of CGCG lesions
while increasing the calcification and
thickening of the cortical Plates.15 Signifi-
cant, stable clinical and radiographic bone
remodelling has been reported after 1 year
of calcitonin treatment of CGCG.12 The
recommended daily dose of calcitonin as a
nasal spray is 200 IU.12 The nasal spray
has the advantage of avoiding daily injec-
tions, and the side effects are considerably
less in comparison with subcutaneous
injections.16 However, the disadvantages
of nasal spray include the low absorption
of calcitonin through the nasal mucosa,
which is variable and ranges between 20%
and 100% when compared to injections.10
Thus, a daily dose of 400 IU calcitonin
nasal spray would be equivalent to as low
as 80 IU and as high as 400 IU of the
injected calcitonin.12 In the present study,
a low dose of nasal calcitonin was used
(200 IU).
All previous studies have used calci-
tonin alone or in conjunction with other
pharmacological agents for the treatment
of CGCGs.2,3,14 In reviewing the litera-
ture, no document regarding the use of
calcitonin for the prevention of recur-
rence after surgical interventions was
identified. de Lange et al. studied calci-
tonin therapy in CGCG of the jaw in 14
patients2; complete remission was not
observed. They reported that changes
in tumour size were variable in patients
with aggressive lesions, whereas a de-
crease or stabilization of the tumour size
occurred for indolent lesions.2 The use
of calcitonin has been suggested as a
supplementary treatment for aggressive
CGCGs.17 The present research showed
a significant reduction in the frequency
Calcitonin for recurrence of CGCG of the jaws 759of recurrence in the group treated with
calcitonin after surgery. It could be hy-
pothesized that the remaining CGCG
lesions after curettage are suppressed
through the CTR.
The re-proliferation of giant cells could
be affected by calcitonin. The administra-
tion of calcitonin has been shown to result
in CTR-mediated alterations in cell struc-
ture and subsequent inhibition of DNA
synthesis by the cells.18 Two distinct
cDNAs encoding the CTRs on CGCGs
have been reported.19 It has been conclud-
ed that the first intracellular domain of the
CTR is involved in ligand binding and
signal transduction via the G protein/ade-
nylate cyclase system.18 Recent evidence
may suggest an association between salm-
on calcitonin use and cancer incidence
based on studies with poor-quality cancer
assessment methods. This evidence may
be considered as a limitation in the use of
calcitonin.20
In this study, calcitonin was used for 3
months after surgery. Tanko et al. showed
that 3 months of calcitonin therapy was
effective in bone formation.21 The use of
calcitonin to reduce recurrence needs fur-
ther study; for example, to determine
whether longer administration of calcito-
nin enhances its prevention capacity or not
(or if an increased dose of calcitonin
affects clinical results). An examination
of CTR was not performed in this study,
which could be considered a limitation.
In conclusion, it appears that calcitonin
nasal spray may reduce the frequency of
recurrence of aggressive CGCGs in the
mandible and maxilla.
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